Lilly reports Q3 2024 financial results highlighted by strong …
INDIANAPOLIS, Oct. 30, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the third quarter of 2024. "Lilly had another strong growth …
All News - Eli Lilly and Company
Oct 28, 2024 · Lilly's latest press releases, stories, news resources and more.
Lilly announces new $4.5 billion site - the Lilly Medicine Foundry
INDIANAPOLIS, Oct. 2, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a $4.5 billion investment to create the Lilly Medicine Foundry, a new center for …
Lilly appoints Thomas J. Fuchs as the company’s first chief AI officer
October 8, 2024. PDF Version. INDIANAPOLIS, Oct. 8, 2024— Today, Eli Lilly and Company (NYSE: LLY) announced the appointment of Thomas J. Fuchs, Dr.sc., as its first chief AI …
Lilly.com | Eli Lilly and Company
INDIANAPOLIS , Oct. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2024 financial results on Oct. 30, 2024 . Lilly will also conduct a …
Lilly hits record high after Mounjaro fuels forecast raise, rival data
Aug 8 (Reuters) - Eli Lilly (LLY.N) on Tuesday raised its annual forecasts as demand for new diabetes drug Mounjaro surges ahead of a decision on its use as a weight-loss treatment, with …
A Medicine Company | Eli Lilly and Company
A Medicine Company | Eli Lilly and Company. Learn the latest information on the availability of Lilly diabetes and obesity medicines. Learn how to protect yourself from counterfeit Mounjaro …
News Release - Eli Lilly and Company
INDIANAPOLIS, May 24, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has more than doubled its investment in its Lebanon, Indiana, manufacturing site …
Eli Lilly and Company - The New York Times
News about Eli Lilly and Company, including commentary and archival articles published in The New York Times.
Lilly drug slows Alzheimer's by 35%, bolstering treatment approach
May 3, 2023 · An experimental Alzheimer's drug developed by Eli Lilly and Co slowed cognitive decline by 35% in a late-stage trial, the company said on Wednesday, providing what experts …